US2023041335A1PendingUtilityA1

Compositions and methods of treating retinal disease

Assignee: ALDEYRA THERAPEUTICS INCPriority: May 26, 2005Filed: Sep 1, 2022Published: Feb 9, 2023

Est. expiryMay 26, 2025(expired)· nominal 20-yr term from priority

Inventors:Thomas A. Jordan John E. Dowling John C. Chabala

C07D 275/00C07C 229/60A61K 31/4706C07D 277/56A61K 31/423A61K 31/41C07D 215/38A61K 31/4418C07C 215/68C07D 277/40A61K 31/44C07C 229/56A61K 31/426A61P 27/02C07D 261/06A61P 27/00A61K 31/47C07D 333/04A61K 31/435A61P 43/00

PatentIndex Score

Cited by

References

Claims

Abstract

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Claims

exact text as granted — not AI-modified

1 - 33 . (canceled) 
     
     
         34 . A compound, which is 
       
         
           
           
               
               
           
         
       
     
     
         35 . A pharmaceutical composition comprising a compound 
       
         
           
           
               
               
           
         
       
       and a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.